In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap
Tags :Janine Corti
Walder Wyss has acted as legal counsel to SkyCell on the completion of a USD 57 million equity financing round at a USD 600 million valuation with M&G Investments, a global investment firm that invests
Pexapark, has raised €20 million in a Series C funding round, which was led by global technology investor Telstra Ventures from San Francisco. Swisscom Ventures and the Spanish A&G Energy Transition Tech Fund also
Under the legal guidance of Bär & Karrer and Walder Wyss, Gebrüder Meier and UIKER Antriebstechnik (UIKER) have come together to enhance their expertise in drive technology within the Swiss market through collaborative
ITS Kanal Services acquired Restclean, a specialist in the field of WC cleaning and renovation. The Swiss ITS Kanal Services is a full-service provider for the maintenance and value preservation of sewer systems and surfaces.
Axiom group, an established investor with a focus on high-growth companies, acquired Swisslinx International and its subsidiary. The acquisition of the Swiss IT staffing and consulting company has been made by Circle8 Group, part of
Nexoya, a startup in Switzerland that focuses on marketing analytics, has closed a successful Series A funding round of USD5 million. The round was led by BlackSheep MadTech Fund and included investments from ZKB and
Fundamenta Group Holding has acquired 100% of the shares of Belvédère Asset Management. In return, the previous shareholders of Belvédère Asset Management will acquire a stake in Fundamenta Group. Following the closing
As we have informed here, Inflexion and Gyrus Capital have entered into an agreement for Inflexion to acquire a majority stake in dss+, a leading provider of operations management consulting services with a purpose of
Bavarian Nordic, a vaccine company, has entered into a definitive agreement to acquire Emergent BioSolutions’ travel vaccines portfolio for up to USD 380 million, including an upfront payment of USD 270 million. With this acquisition of Maryland’
